The CCL2-CCR2 axis in primary lung cancer and pulmonary metastasis: from molecular mechanisms to therapeutic potentials
Yujie Huang, Jia Ma, JianPing Bi, Guoliang Pi, Ying Li, Yi Peng, Chuangying Xiao, Xiulin Tuo, Guang Han · 2026
Read The CCL2-CCR2 axis in primary lung cancer and pulmonary metastasis: from molecular mechanisms to therapeutic potentials by Yujie Huang, Jia Ma, JianPing Bi, Guoliang Pi, Ying Li, Yi Peng, Chuangying Xiao, Xiulin Tuo, Guang Han (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13602120.txt.
Description
Huang and co-authors reviewed the CCL2-CCR2 signaling axis, a chemical call-and-receptor pair that draws immune cells into lung tumors. Lung cancer kills more people than any other cancer, and spread, drug resistance, and a suppressive tumor environment drive that toll. This pathway recruits monocytes and other cells that help tumors grow blood vessels, invade, spread, and shrug off chemotherapy, targeted drugs, and immunotherapy.
The review maps how the signal links into major cancer pathways and notes rare settings where it seems to fight tumors instead. It then surveys treatments aimed at the axis, including receptor blockers and signal-neutralizing agents, plus combinations with immune checkpoint drugs. The authors judge the case for targeting the pathway strong but early: well-designed clinical trials are still needed before doctors can know whether blocking it helps patients.
Catalog record
| CREATOR | Yujie Huang, Jia Ma, JianPing Bi, Guoliang Pi, Ying Li, Yi Peng, Chuangying Xiao, Xiulin Tuo, Guang Han |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 113 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |